Skip to main content

AACC 2018

Novosanis will be attending AACC in Chicago, US from July 30 to Agust 2, 2018. Our Sales & Business Development Director LATAM & US, Jeane Brunmark is excited to meet you and provide insights in our solutions for (home-based) urine sampling for detection of infectious diseases and early-stage cancer.

The conference has its 70th edition and will host a large number of exhibitors next to having an exciting scientific programme. Jeane Brunmark, our Sales & Business Development Director for LATAM and US will represent Novosanis at the conference. Feel free to invite her for a chat and get more insights in our urine self-sampling solution, Colli-Pee.

AACC

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.